evolocumab in different cv risk groups, prof. dr. nabil farag, 16-march-2022
Published 2 years ago • 1.6K plays • Length 48:13Download video MP4
Download video MP3
Similar videos
-
1:10:10
coronary intervention in patients with ckd. prof. gamal fahim and prof. nabil farag, 29 october 2020
-
14:32
the future of patient care and the economic value of robotic-assisted surgery
-
38:53
aorto-ostial lesions, prof. dr. nabil farag
-
0:38
cryovein and cryoartery vs. other processors_ml0562.000
-
2:12
the future generation of cvi cardiologists - eacvi club 35
-
1:10
atrial fibrillation explained - best selling book - understanding the next cardiac epidemic
-
7:19
evolut pro: a legacy of superior outcomes - jeffrey popma, md
-
0:54
prof steve nicholls: is there a link between the benefit of evolocumab observed in glagov & fourier?
-
10:22
what to look for in a new cardiovacular information system
-
0:45
probonix testimonial - clostridium difficile (c. diff)
-
![brand vs generic rivaroxaban atrial fibrillation – video abstract [459658]](https://i.ytimg.com/vi/yFoM9Cvhh6k/mqdefault.jpg)
3:38
brand vs generic rivaroxaban atrial fibrillation – video abstract [459658]
-
14:19
the international, multicentre, prospective bivolutx registry - #europcr 2023
-
5:51
tavr device approval and results of the extreme risk study
-
6:01
a health innovator's quest for validation
-
1:36
what are the key innovations in haematology in the past 60 years?
-
5:14
filippo crea: “ischemic heart disease: the main cause of morbidity and mortality."
-
![[tctap 2024] live case 10: valve-in-valve, complex tavr](https://i.ytimg.com/vi/KpxT_8JPn4A/mqdefault.jpg)
1:21:01
[tctap 2024] live case 10: valve-in-valve, complex tavr
-
1:26:41
dr nabil farg - module 1